|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT03106259 |
|
Date of registration:
|
03/04/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj
|
|
Scientific title:
|
Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj |
|
Date of first enrolment:
|
June 29, 2016 |
|
Target sample size:
|
9 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT03106259 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Korea, Republic of
| | | | | | | |
|
Contacts
|
|
Name:
|
Ki-chul Shin |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
SMG-SNU Boramae Medical Center |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Subjects participating in this observational study originally participated in study
FURESTEM-RA Inj.[NCT02221258]
- Subject who understands and voluntarily sign an informed consent form
Exclusion Criteria:
- In case follow-up is not possible from end of clinical trial Phase 1 to end of this
study period
Age minimum:
19 Years
Age maximum:
80 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Rheumatoid Arthritis
|
|
Intervention(s)
|
|
Drug: FURESTEM-RA Inj.
|
|
Primary Outcome(s)
|
|
Safety of FURESTEM-RA Inj.
[Time Frame: 5 years]
|
|
Secondary ID(s)
|
|
KSTBT_FURESTEM_RA_EXT
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|